PBM Kickback Prohibition Act
Summary
HR7895 is an early-stage House bill banning referral compensation to PBMs. It has no Senate companion, sits at the start of the legislative process, and has near-zero passage probability in this Congress. Market data shows the three largest PBM-associated stocks (CVS, UNH, CI) have rallied significantly over the past 30 days — this bill is not a driver of those moves. The bill's impact, if enacted, would be immaterial to all three companies' financials.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7895 is early-stage, low-priority legislation with near-zero passage probability this Congress.
- 2.The bill targets a narrow, non-core PBM revenue stream — referral compensation — not drug pricing or rebates.
- 3.Even if enacted, financial impact on CVS, UNH, and CI would be immaterial relative to total revenues.
- 4.Current market rallies in CVS (+16% 30-day), UNH (+36%), and CI (+10%) are unrelated to this bill.
Market Implications
No material market implication from this bill. CVS at $83.41, UNH at $368.70, and CI at $292.30 have rallied strongly over the past 30 days on earnings and sector dynamics — not on any PBM regulatory shift. This bill is not a catalyst for any of the three tickers. The 52-week ranges show CVS near its high, UNH well off its low but below its high of $411.99, and CI in the middle of its range. Investors should not factor this bill into positions on any of these stocks.
Full Analysis
What happened: On March 12, 2026, Rep. Rick Allen (R-GA) introduced H.R. 7895, the PBM Kickback Prohibition Act. The bill amends ERISA Section 408 to bar pharmacy benefit managers from paying compensation to brokers or advisors for the referral of plan business. The bill was referred to the House Committee on Education and Workforce. As of April 30, 2026, no further action has occurred — no hearings, markup, or Senate companion bill.
The money trail: The bill authorizes $0 in federal spending. It imposes a regulatory prohibition on private sector payment arrangements. No taxpayer funds are involved. No appropriations process is required. The economic effect is purely a removal of a specific private payment stream between PBMs and referral intermediaries.
Structural winners and losers: This bill, if enacted, would theoretically reduce one very narrow cost stream for the three largest PBMs — CVS Caremark, Optum Rx, and Express Scripts. However, referral compensation is a minor, non-core revenue source. None of these companies break out referral fees as a material segment driver. The actual competitive positioning of these PBMs is driven by formulary management, rebate negotiation, and pharmacy network breadth — none of which this bill touches.
Real market data context: Over the past 30 days (March 31 to April 30, 2026), has risen 16.12%, has surged 36.26%, and has gained 9.58%. These moves are driven by earnings, sector rotation, or other market factors — not by this bill. The bill was introduced on March 12 and has generated zero price reaction. At $83.41, is trading near its 52-week high of $85.15. at $368.70 is well above its 52-week low of $234.60. at $292.30 sits roughly in the middle of its 52-week range. The 30-day rallies predate and post-date the bill's introduction without any visible inflection.
Timeline: The bill is at the earliest stage of the legislative process — introduced, referred to committee, no schedule for hearing or markup. With no Senate companion and limited sponsor seniority (Rep. Allen is a junior House Republican), the probability of enactment in the 119th Congress is near zero. Even if it moved, the effective date applies only to plan years beginning after enactment, meaning any real-world impact would be years away.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
GEORGIA DEPARTMENT OF COMMUNITY HEALTH: $14.2B Department of Health and Human Services Grant
MINNESOTA DEPARTMENT OF HUMAN SERVICES: $13.6B Department of Health and Human Services Grant
MINNESOTA DEPARTMENT OF HUMAN SERVICES: $11.3B Department of Health and Human Services Grant
STATE OF RHODE ISLAND DEPARTMENT OF ADMINISTRATION: $2.8B Department of Health and Human Services Grant
DEPARTMENT OF SOCIAL SERVICES CALIFORNIA: $1.5B Department of Health and Human Services Grant
NORTH CAROLINA DEPARTMENT OF PUBLIC SAFETY: $2.5B Department of Homeland Security Grant
GEORGIA EMERGENCY MANAGEMENT AND HOMELAND SECURITY AGENCY: $1.7B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.6B Department of Homeland Security Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →